The kinase domains of ALK and ROS1 fusion proteins display highly homology, implying that ALK-TKI, such as crizotinib, will be also effective for ROS1 rearrangement-positive NSCLC patients [12]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.